Cardiff Oncology (CRDF) Interest Expenses (2011 - 2026)

Cardiff Oncology has reported Interest Expenses for 15 years, with the latest figure at $57.3 million in Q4 2025.

• Quarterly Interest Expenses rose 390.72% year-over-year to $57.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $57.3 million (up 390.72% YoY) and the FY2025 annual result came in at $57.3 million, up 18.23% from the prior year.
• Interest Expenses rose to $57.3 million in Q4 2025 per CRDF's latest filing, from $759735.0 in the prior quarter.
• Over five years, Interest Expenses peaked at $57.3 million in Q4 2025 and troughed at $181000.0 in Q4 2022.
• A 5-year average of $8.9 million and a median of $3.6 million in 2022 frame the typical range for Interest Expenses.
• The widest YoY moves for Interest Expenses: up 21541.44% in 2023, down 89.81% in 2023.
• Over 5 years, Interest Expenses stood at $223000.0 in 2021, then slipped by 18.83% to $181000.0 in 2022, then jumped by 21541.44% to $39.2 million in 2023, then sank by 70.21% to $11.7 million in 2024, then surged by 390.72% to $57.3 million in 2025.
• According to Business Quant data, Interest Expenses over the past three periods registered $57.3 million, $759735.0, and $4.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.